Medications

Every FDA-Approved GLP-1 Medication (2026 List)

A complete, sourced list of every GLP-1 receptor agonist medication approved and sold in the United States as of September 2026, including what each one treats, what it costs and which ones have been discontinued.

Last verified September 14, 2026·19 sources cited·Ozempic Wegovy

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

The GLP-1 shelf got a lot more crowded in the last year. Two oral weight-loss drugs arrived, a higher-dose Wegovy pen was approved, one brand name disappeared, and two older products were pulled from the market entirely.

This is the full list of what is actually approved and sold in the United States as of September 2026, what each one treats, and what it costs. Every entry points back to a label or a company announcement.

What counts as a GLP-1 medication?

GLP-1 receptor agonists copy a gut hormone called glucagon-like peptide-1. They prompt the pancreas to release insulin when blood sugar rises, slow how quickly the stomach empties, and dial down appetite signaling.

One product on this list, tirzepatide, activates a second receptor called GIP as well. People lump it in with GLP-1s in everyday conversation, and so does most insurance paperwork, so it is included here with that caveat noted.

Which GLP-1 medications are approved for weight loss?

Six product families carry a weight-management indication.

Wegovy (semaglutide) injection

Approved June 4, 2021 for adults, extended to adolescents 12 and older in December 2022 [2]. Once weekly, injected under the skin. The label now covers three things: weight reduction, cardiovascular risk reduction in people with established heart disease and obesity or overweight, and, under accelerated approval since August 2025, noncirrhotic MASH with moderate to advanced liver fibrosis [2].

Doses step up over 16 weeks: 0.25, 0.5, 1, 1.7 mg, then maintenance at 2.4 mg (or 1.7 mg as an alternative) [2].

Wegovy HD (semaglutide) 7.2 mg injection

Approved March 19, 2026 and available across US pharmacies from April 7, 2026. The label allows moving to 7.2 mg only for adults who have tolerated 2.4 mg for at least four weeks and need additional weight reduction [2]. It reaches weight loss of roughly 20.7% at 72 weeks in trial participants who stayed on treatment. Self-pay price is $399 a month.

Wegovy tablets (oral semaglutide 25 mg)

Approved December 22, 2025, reaching US pharmacies January 5, 2026. The first oral GLP-1 approved for weight management in the US. Strengths are 1.5, 4, 9 and 25 mg, stepping up every 30 days to a 25 mg maintenance dose from day 91 [2]. It also carries the cardiovascular risk-reduction indication. Taken on an empty stomach with a 30-minute wait before food or other medicines.

Zepbound (tirzepatide) injection

Approved November 8, 2023 for chronic weight management, and on December 20, 2024 it became the first and only prescription medicine approved for moderate-to-severe obstructive sleep apnea in adults with obesity [4]. Doses start at 2.5 mg weekly and go up in 2.5 mg steps to a maximum of 15 mg. Maintenance is 5, 10 or 15 mg for weight, and 10 or 15 mg for sleep apnea [4].

Zepbound now comes four ways: single-dose pens, single-dose vials, multi-dose vials and a four-dose KwikPen that became available February 23, 2026 and reached self-pay pricing at major pharmacies nationwide on March 13, 2026.

Foundayo (orforglipron) tablets

Approved April 1, 2026 and the newest GLP-1 on the market [10]. It is a non-peptide small molecule, which matters practically: the label says it can be taken any time of day, with or without food, and there is no water restriction or waiting period. Strengths are 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg, escalating on 30-day steps to a maximum of 17.2 mg [6].

In the ATTAIN-1 trial, participants on the highest dose who stayed on treatment (the efficacy estimand) lost an average of 27.3 pounds, or 12.4%, over 72 weeks, versus 2.2 pounds (0.9%) on placebo [10]. One wrinkle that trips up comparisons: the trial reported that dose as a 36 mg investigational capsule, which is equivalent to the marketed 17.2 mg Foundayo tablet, so the trial milligram figure and the bottle milligram figure do not match.

Saxenda (liraglutide) 3 mg and its generic

The oldest weight-management GLP-1 still sold. It is injected daily, not weekly, in a multi-dose pen delivering up to 3 mg [8]. Its label includes a stopping rule most newer drugs do not have: adults are told to discontinue if they have not lost 4% of body weight by 16 weeks.

Teva launched the first generic version on August 28, 2025, making it the only generic GLP-1 in the US indicated for weight loss [12].

Which GLP-1 medications are approved for type 2 diabetes?

Ozempic (semaglutide) injection

Approved December 5, 2017. Once weekly at 0.25, 0.5, 1 or 2 mg. Its label covers blood sugar control, cardiovascular risk reduction and, uniquely in the class, slowing chronic kidney disease progression in adults with type 2 diabetes [1]. A single-dose prefilled syringe presentation now appears in the label alongside the familiar multi-dose pens.

Ozempic tablets (the Ozempic pill)

Launched May 4, 2026 at 1.5, 4 and 9 mg. This is the reformulated oral semaglutide previously sold as Rybelsus; FDA approved the Ozempic name for it on January 30, 2026 [3]. It is approved for blood sugar control and for reducing major adverse cardiovascular events in adults with type 2 diabetes at high risk.

Rybelsus (semaglutide) tablets 3, 7 and 14 mg

Approved September 20, 2019. The brand name has been retired in the United States, though the strengths still appear in the shared prescribing information along with a table for switching to the Ozempic tablet doses [3].

Mounjaro (tirzepatide) injection

Approved May 13, 2022. Its label has grown twice recently: to pediatric patients aged 10 and older with type 2 diabetes, based on SURPASS-PEDS (the Pediatric Endocrine Society reported the expansion on February 24, 2026; Eli Lilly did not issue a press release and no exact FDA action date has been published), and on August 28, 2026 to reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk [5][19]. Doses run 2.5 mg to 15 mg weekly in adults, with a 10 mg ceiling in children.

Trulicity (dulaglutide) injection

Eli Lilly’s once-weekly GLP-1 for type 2 diabetes, still sold in 0.75, 1.5, 3 and 4.5 mg single-dose pens [7]. It was one of the most prescribed GLP-1s before semaglutide and tirzepatide overtook it. Lilly’s own pricing page puts the list price at $1,006.93 a month, where a month is four pens; the federal TrumpRx site shows a slightly different list figure, $987.19. Neither is a patient price. Trulicity is listed on TrumpRx at a self-pay price of $389 a month, fulfilled through LillyDirect.

Victoza (liraglutide) injection and its generics

A once-daily injection for type 2 diabetes in adults and children 10 and older, delivered from an 18 mg/3 mL pen at 0.6, 1.2 or 1.8 mg [9]. Generic liraglutide referencing Victoza has been on the US market since late 2024 from Hikma, Teva and others.

Which GLP-1 medications have been discontinued?

Byetta (exenatide) was the first GLP-1 ever approved, in 2005, taken twice daily before meals. AstraZeneca discontinued it in the US on October 25, 2024 [11].

Bydureon BCise (exenatide extended-release) was the once-weekly version, approved down to age 10 in 2021. AstraZeneca discontinued it on October 28, 2024 [11]. All Bydureon products have now been withdrawn worldwide.

If you are still searching for either, they are gone. A healthcare provider can discuss what is available instead.

What is coming next?

CagriSema is Novo Nordisk’s once-weekly combination of semaglutide with the amylin analog cagrilintide. The company filed with FDA on December 18, 2025 [13]. It is not approved as of September 14, 2026, and Novo Nordisk has not published a PDUFA date; the company has said only that it anticipates a decision in 2026, and industry trackers place it in the fourth quarter. In the open-label REDEFINE 4 trial reported February 23, 2026, it produced about 23% weight loss at 84 weeks but did not meet its noninferiority endpoint against tirzepatide 15 mg [13]. Treat any website claiming CagriSema is already approved as wrong.

A 25 mg Ozempic tablet has been filed with FDA as a supplemental application. Novo Nordisk’s own May 1, 2026 announcement says the company expects an FDA decision by the end of 2026 [3].

Wegovy vials have been signaled by Novo Nordisk in press reporting, but no vial appears in the US Wegovy label as of September 2026. Treat this as a plan, not a product.

What do these medications cost in 2026?

Cash-pay prices have moved a long way from list price. These are the published manufacturer self-pay prices as of September 2026.

Medicine	Self-pay per month
Wegovy pen (standard doses)	$349 ($199 intro for first 2 fills of the two starting doses, new patients, through Dec 31 2026)
Wegovy HD 7.2 mg	$399
Wegovy tablets	$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg)
Ozempic pen	$349 (0.25, 0.5, 1 mg), $499 (2 mg)
Ozempic tablets	$149 (1.5 mg), $199 (4 mg), $299 (9 mg)
Zepbound vial or KwikPen (LillyDirect)	$299 (2.5 mg), $399 (5 mg), $449 (7.5-15 mg with a refill inside 45 days; without one, $499 for 7.5 mg and $699 for 10-15 mg)
Foundayo (LillyDirect)	$149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9, 14.5, 17.2 mg)

People with commercial insurance that covers the drug may pay as little as $25 a month on most of these, subject to program caps. Government beneficiaries are excluded from copay cards.

Separately, eligible Medicare Part D enrollees can get certain GLP-1 medications for $50 a month under the CMS Medicare GLP-1 Bridge demonstration, which runs from July 1, 2026 through December 31, 2027 [18]. CMS’s own fact sheet names exactly three: Foundayo tablets, Wegovy injection or tablets, and Zepbound — but the Zepbound KwikPen only, stating that the single-dose Zepbound pen and Zepbound vials are not covered. Ozempic and Mounjaro are not covered by the Bridge.

When will these drugs go generic?

For semaglutide, not soon in the United States. Orange Book listings for Ozempic show the core compound patents expiring December 5, 2031, with method-of-use patents running to June 21, 2033 [14]. Novo Nordisk’s own 2025 annual report (Form 20-F) states the US compound patent expiry for Ozempic, Rybelsus and Wegovy as 2032, which is the December 2031 patent plus pediatric exclusivity [15].

Two wrinkles are worth knowing. Apotex has received tentative FDA approval for a generic semaglutide, meaning FDA judged the application adequate but cannot grant final approval while patents and exclusivities stand. And Novo Nordisk has settled US Ozempic patent litigation with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex on confidential terms [15]. Confidential settlements sometimes set an entry date earlier than patent expiry, so no one outside those agreements can state a firm US launch date. Treat any specific “generic Ozempic launch date” you see online as speculation.

Canada is a different story. A Canadian patent lapsed after a missed maintenance fee, and Health Canada approved Dr. Reddy’s generic semaglutide injection on April 28, 2026 - the first generic semaglutide approved in any G7 country [15][16]. Apotex followed on May 1, 2026 [16], and Hims & Hers began offering the Apotex product to Canadian patients on May 21, 2026 [17]. None of that changes what is legally available in US pharmacies.

Liraglutide is the exception: generics exist for both Victoza and Saxenda.

What is not on this list?

Compounded semaglutide, “research-grade” peptides sold online, and imported generics are not FDA-approved products. They have no approved label, no NDC and no FDA review of quality or potency. FDA has also seized counterfeit Ozempic pens from the legitimate supply chain three times since 2023. If a price looks impossible, that is the thing to check first.

Sources

This article is general information, not medical advice. Talk to a healthcare provider about which medicine, if any, is appropriate for you.

Questions people ask

How many GLP-1 medications are FDA approved right now?

As of September 2026 there are eight marketed brand families in the United States: Ozempic (injection and tablets), Wegovy (injection and tablets), Mounjaro, Zepbound, Foundayo, Trulicity, Victoza and Saxenda, plus generic liraglutide referencing both Victoza and Saxenda. Byetta and Bydureon BCise were discontinued in October 2024.

Which GLP-1 medications are approved for weight loss?

Wegovy injection (including Wegovy HD 7.2 mg), Wegovy tablets, Zepbound, Foundayo (orforglipron), Saxenda and generic liraglutide 3 mg. Ozempic, Mounjaro, Trulicity, Victoza and Rybelsus are approved for type 2 diabetes, not weight management.

What is the newest GLP-1 drug?

Foundayo (orforglipron), approved April 1, 2026. It is a once-daily small-molecule oral GLP-1 for chronic weight management and the only GLP-1 pill that can be taken any time of day without food or water restrictions.

Is CagriSema approved by the FDA?

No. Novo Nordisk submitted a New Drug Application on December 18, 2025 for CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg). As of September 14, 2026 it remains under review. Novo Nordisk has said it anticipates an FDA decision in 2026 and industry trackers place it in the fourth quarter, but neither FDA nor Novo Nordisk has published a PDUFA date.

Is there a generic version of Ozempic or Wegovy?

Not in the United States. Orange Book listings show the core semaglutide compound patents running to December 5, 2031, with method-of-use patents to June 2033, and Novo Nordisk's own 2025 Form 20-F gives 2032 as the US compound patent expiry. Apotex holds a tentative FDA approval, and Novo Nordisk has settled US Ozempic patent litigation with several generic filers on confidential terms, so no firm US launch date is public. Canada approved its first generic semaglutide on April 28, 2026 after a Canadian patent lapsed, but that has no effect on US availability.

Which GLP-1 is the cheapest?

Generic liraglutide, launched for Saxenda in August 2025, is the lowest-cost FDA-approved injectable GLP-1 for weight management in most markets. It is an older molecule taken daily rather than weekly and produces less average weight loss than semaglutide or tirzepatide. Among brands, the cheapest cash-pay starting doses in 2026 are the oral products at $149 a month (verified 2026-09-14).

Are Byetta and Bydureon still available?

No. AstraZeneca discontinued Byetta on October 25, 2024 and Bydureon BCise on October 28, 2024. Both exenatide products have been withdrawn.

Is tirzepatide a GLP-1?

Tirzepatide, sold as Mounjaro and Zepbound, activates two receptors: GIP and GLP-1. It is usually grouped with the GLP-1 class in everyday use, but technically it is a dual agonist, not a pure GLP-1 receptor agonist like semaglutide.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.